# Thalidomide Analogue - Revlimid (lenalidomide)

|            |                         |
| ---------- | ----------------------- |
| Criteria 1 | Revlimid (lenalidomide) |

  

 

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Thalidomide Analogue</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Revlimid (lenalidomide)</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th><strong>Preferred</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Non-Preferred</strong></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Brand</strong></td>
<td></td>
</tr>
<tr class="odd">
<td><strong>Generic</strong></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Other</strong></td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>REVLIMID</td>
<td>060230</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>REVLIMID</td>
<td>060231</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>REVLIMID</td>
<td>061113</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>REVLIMID</td>
<td>061114</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>REVLIMID</td>
<td>068980</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>REVLIMID</td>
<td>071056</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

 

| **Sequence Number** | **Question ID** | **Default Next Question ID** | **Question Type** | **Question Text**                                                                                         | **Choice Text**             | **Next Question ID**     |
| ------------------- | --------------- | ---------------------------- | ----------------- | --------------------------------------------------------------------------------------------------------- | --------------------------- | ------------------------ |
| 1                   | 1000            |                              | Select            | Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling? | Y                           | 1001                     |
|                     |                 |                              |                   |                                                                                                           | N                           | 1235                     |
| 2                   | 1001            |                              | Select            | Are the patient and prescriber enrolled in the Risk Evaluation and Mitigation Strategies (REMS) program?  | Y                           | END (Approve x 365 days) |
|                     |                 |                              |                   |                                                                                                           | N                           | 1235                     |
| 3                   | 1235            |                              | Free Text         | Please provide the rationale for the medication being requested.                                          | END (Pending Manual Review) |                          |

LENGTH OF AUTHORIZATIONS: 365 Days

| **Last Approved ** | 4/13/2023 |
| ------------------ | --------- |
| **Other**          |           |
